Skip to content
10-K

Annual Report

IOVANCE BIOTHERAPEUTICS, INC. IOVA

0001104659-26-018899

← back to feed
Filed
Feb 24, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 13, 2026 411.96M sh
Shares Diluted FY 2025 · Dec 31, 2025 357.35K sh
Shares Diluted FY 2025 · Dec 31, 2024 289.88K sh
Shares Diluted FY 2025 · Dec 31, 2023 235.13K sh
Capex FY 2025 · Dec 31, 2025 $33.84M
Capex FY 2025 · Dec 31, 2024 $11.07M
Capex FY 2025 · Dec 31, 2023 $22.29M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$302.41M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$352.98M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$361.82M
Short Term Investments FY 2025 · Dec 31, 2025 $133.9M
Short Term Investments FY 2025 · Dec 31, 2024 $208.09M
Cash And Equivalents FY 2025 · Dec 31, 2025 $163.08M
Cash And Equivalents FY 2025 · Dec 31, 2024 $115.69M
Cash And Equivalents FY 2025 · Dec 31, 2023 $114.89M
Stockholders Equity FY 2025 · Dec 31, 2025 $698.58M
Stockholders Equity FY 2025 · Dec 31, 2024 $710.41M
Stockholders Equity FY 2025 · Dec 31, 2023 $584.61M
Stockholders Equity FY 2025 · Dec 31, 2022 $499.64M
Current Liabilities FY 2025 · Dec 31, 2025 $138.36M
Current Liabilities FY 2025 · Dec 31, 2024 $122.34M
Total Liabilities FY 2025 · Dec 31, 2025 $214.59M
Total Liabilities FY 2025 · Dec 31, 2024 $200.02M
Current Assets FY 2025 · Dec 31, 2025 $442.69M
Current Assets FY 2025 · Dec 31, 2024 $457.02M
Total Assets FY 2025 · Dec 31, 2025 $913.17M
Total Assets FY 2025 · Dec 31, 2024 $910.43M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.09
Eps Diluted FY 2025 · Dec 31, 2024 −$1.28
Eps Diluted FY 2025 · Dec 31, 2023 −$1.89
Eps Basic FY 2025 · Dec 31, 2025 −$1.09
Eps Basic FY 2025 · Dec 31, 2024 −$1.28
Eps Basic FY 2025 · Dec 31, 2023 −$1.89
Sga Expense FY 2025 · Dec 31, 2025 $152.32M
Sga Expense restated FY 2025 · Dec 31, 2024 $152.27M
Sga Expense restated FY 2025 · Dec 31, 2023 $106.1M
Rd Expense FY 2025 · Dec 31, 2025 $300.27M
Rd Expense restated FY 2025 · Dec 31, 2024 $276.23M
Rd Expense restated FY 2025 · Dec 31, 2023 $333.19M
Net Income FY 2025 · Dec 31, 2025 −$390.98M
Net Income FY 2025 · Dec 31, 2024 −$372.18M
Net Income FY 2025 · Dec 31, 2023 −$444.04M
Operating Income FY 2025 · Dec 31, 2025 −$403.36M
Operating Income FY 2025 · Dec 31, 2024 −$395.28M
Operating Income FY 2025 · Dec 31, 2023 −$460.56M
Cost Of Revenue FY 2025 · Dec 31, 2025 $173.18M
Cost Of Revenue restated FY 2025 · Dec 31, 2024 $93.25M
Cost Of Revenue restated FY 2025 · Dec 31, 2023 $1.03M
Revenue FY 2025 · Dec 31, 2025 $263.5M
Revenue FY 2025 · Dec 31, 2024 $164.07M
Revenue FY 2025 · Dec 31, 2023 $1.19M